Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cubist licenses daptomycin from Lilly

Executive Summary

Cubist Pharmaceuticals acquired exclusive rights to Eli Lilly's Phase II daptomycin to treat diseases caused by Staphylococcus aureus and enterococcus bacteria. Financial terms include a license fee, milestone payments, and royalties.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing-Licensing
    • Includes Contract
    • Reverse Licensing
    • Includes Equity

Related Companies

Advertisement
UsernamePublicRestriction

Register